CD46 and breast carcinoma: Before investigating the antitumor activity of CRAd-synNotch and ADX730 in T24 (MIBC) and BT474 (a COX-2 negative human breast cancer cell line) cells, we confirmed the expressions of CAR, CD46 and CD44 expressions on the cell surface.